Skip to content

USE OF AN OPD DRUG TO PREVENT PROLONGED PREGNANCY

OUTPATIENT-BASED MISOPROSTOL TO PREVENT PROLONGED PREGNANCY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/09/005006
Enrollment
130
Registered
2014-09-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- uncomplicated singleton pregnant women at 40 weeks of gestation

Interventions

Intervention1: Misoprostol: Single low dose (25 µg) misoprostol vaginally given on outpatient basis at 40 completed weeks of gestation Control Intervention1: nil: no intervention

Sponsors

University College of Medical Sciences and Guru Teg Bahadur HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Total number of 130 subjects of uncomplicated singleton pregnancy at 40 completed weeks (gestational age based on LMP or scan before 20 weeks of gestation) of gestation with vertex presentation with Bishop score ï?£5. • Intact membranes or no leaking per-vaginum • No contraindication for vaginal delivery • Normal Biophysical profile

Exclusion criteria

Exclusion criteria: • Grand multiparity (ï?³5) • Any maternal systemic disease • Previous LSCS / uterine scar • Unexplained vaginal bleeding • EFW >3.5 kg • Fetal growth restriction, oligohydramnios (AFI ï?£5) • Fetal anomalies • Contraindications for misoprostol (allergy, cardiovascular diseases, renal impairment etc.)

Design outcomes

Primary

MeasureTime frame
â?¢ Number of women entering spontaneous labor between 40 to 41 weeks of gestationTimepoint: 41 weeks of gestation or spontaneous labor (which ever is earlier)

Secondary

MeasureTime frame
â?¢ Time from enrolment in study till delivery â?¢ Need for cesarean section â?¢ Neonatal outcome in early neonatal age (Apgar score at 1 and 5 minutes, meconium stained liquor, neonatal morbidity and mortality) â?¢ Side effects of misoprostol in mother (nausea, vomiting, diarrhea, fever and abnormal uterine activity, etc.) Timepoint: one week

Countries

India

Contacts

Public ContactNIKITA JINDAL

DEPARTMENT OF OBG, UCMS & GTB HOSPITAL

nbvaid@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026